Revenues for the third quarter of $17.5 million , up 165% over prior-year quarter, driven by increased RT-PCR COVID-19 testing, resulting in profitability; cash balance of $27.7 million at quarter-end Robust CNSide™ sequential-quarter volume growth; continued customer base expansion Data generated
Abstract published in the Journal of Molecular Diagnostics shows 200-1,000 times increase in assay sensitivity with the addition of Switch-Blocker technology SAN DIEGO --(BUSINESS WIRE)--Nov. 9, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and
SAN DIEGO --(BUSINESS WIRE)--Nov. 8, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and nine months ended September 30, 2021 after the market closes on Monday, November 15,
SAN DIEGO --(BUSINESS WIRE)--Oct. 6, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall , President and CEO, will present a company overview at the LD Micro Main Event on Wednesday, October 13, 2021 at 11:00
Company has received more than 570,000 samples since launching its COVID-19 testing services in 2020 for skilled nursing homes, businesses, college campuses, health care facilities, and other venues SAN DIEGO --(BUSINESS WIRE)--Sep. 22, 2021-- Biocept, Inc .
Company’s ultra-sensitive and quantitative assays support efforts to develop targeted therapies for cancers driven by a variety of genetic mutations SAN DIEGO --(BUSINESS WIRE)--Sep. 21, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, will present data
SAN DIEGO --(BUSINESS WIRE)--Sep. 7, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, announces that Michael Nall , President and CEO, will present at four upcoming investor conferences as follows: H.C. Wainwright 23 rd Annual Global Investment
SAN DIEGO --(BUSINESS WIRE)--Aug. 31, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that it has granted inducement stock options to purchase an aggregate of 220,800 shares of its common stock to 16 new employees.
Study to be presented at the Society for Neuro-Oncology Third Annual Conference on Brain Metastases, Aug. 19-20 SAN DIEGO --(BUSINESS WIRE)--Aug. 19, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that new data show the company’s
Second quarter revenues of $12.0 million driven by RT-PCR COVID-19 testing Continued sequential-quarter CNSide™ volume growth with customer base expanding to more than 30 leading U.S. academic institutions, including multiple repeat users Issued coverage with high-value payment by Medicare for the
